Compare General Mills, Inc. (GIS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Viatris Inc — how do they compare? General Mills, Inc. trades at $38.24 (market cap $20.24B), while Viatris Inc trades at $16.25 (market cap $18.69B). The key difference: General Mills, Inc. and Viatris Inc are close in size by market cap, and General Mills, Inc. pays the higher dividend (6.43%). Which is the better fit depends on your goals.
| GIS | VTRS | |
|---|---|---|
Market Cap | $20.24B | $18.69B |
Sector | Consumer Staples | Health |
52-Week High | $51.11 | $17.86 |
52-Week Low | $32.17 | $9.49 |
Enterprise Value | $33.73B | $30.80B |
Dividend Yield | 6.43% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $37.97, up 1.89% today, showing a mixed technical picture with a bullish moving average signal but a neutral RSI. Fundamentally, the company reported a net loss in 2026, compressing margins, though it beat Q2 2026 EPS estimates. Recent news highlights strategic partnerships in regenerative agriculture and new product launches to drive growth amid challenging consumer demand.
The outlook is cautious; while the stock appears undervalued on a P/E basis and offers a dividend, significant risks include persistent margin pressure, high debt levels, and weak sales growth. Analyst consensus is predominantly Hold, reflecting uncertainty about the company's turnaround efforts in a competitive market.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
